View printer-friendly version << Back

Novavax to Present at the University of Maryland 'Avian Flu: What Can We Do?' Symposium

MALVERN, Pa., Jan. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Avian Flu Symposium sponsored by the University of Maryland Center for Health and Homeland Security on Friday, January 13, 2006. Dr. Singhvi will discuss a worst-case pandemic influenza scenario and how existing and new vaccine technology could address the need for hundreds of millions of doses of vaccine within months rather than years.

    PRESENTATION TITLE:  "Strategies for Rapid Response, Surge Capacity, and
     Dose Sparing with New Flu Vaccine Technology"

    WHEN: Friday, January 13, 2006, 10:35 a.m. (EST)

    WHERE: University of Maryland School of Law, 500 West Baltimore Street,
     Baltimore, Maryland

    REGISTRATION:  Available through:

About Novavax, Inc.

Novavax, Inc. is a product development company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) (paucillamellar non-phospholipid liposomes) and Sterisomes(R) (subcutaneous depot injection). Novavax's vaccine technologies include its virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies.

SOURCE Novavax, Inc.

CONTACT: Kathy Hamilton, Investor Relations of Novavax, Inc., +1-484-913-1213, or